Repligen Corp. 10-Q Summary: Quarter Ended June 30, 2009
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Repligen Corporation for the three-month period ended June 30, 2009. Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases and operating a bioprocessing business selling Protein A products for monoclonal antibody purification. The company also receives royalties from Bristol-Myers Squibb (Bristol) regarding the drug Orencia.
Key Financial Metrics
| Metric | Q2 2009 | Q2 2008 |
|---|---|---|
| Total Revenue | $5,060,853 | $13,660,245 |
| Net (Loss) Income | $(1,105,980) | $8,278,828 |
| Operating Loss | $(1,427,723) | $7,958,148 (Income) |
| Cash from Operations | $(1,867,626) | $5,636,978 |
| Cash & Equivalents (End of Period) | $3,670,604 | $33,458,367 |
| Total Assets | $71,455,664 | $73,754,742 |
| Total Liabilities | $3,197,502 | $4,631,311 |
| Working Capital | $50,327,307 | $50,234,803 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 63% ($8.6 million) compared to the prior year. This was driven by a 55% drop in Protein A product sales due to decreased customer demand and a significant reduction in royalty revenue from Bristol.
- Royalty Revenue Volatility: Royalty revenue from Bristol dropped from $7.9 million in Q2 2008 to $2.1 million in Q2 2009. The 2008 figure included a one-time $5.0 million initial settlement payment which was not present in 2009.
- Profitability Shift: The company swung from a net income of $8.3 million in Q2 2008 to a net loss of $1.1 million in Q2 2009.
- Expense Increases: Research and development (R&D) expenses increased by 62% ($1.3 million) to $3.4 million, driven by clinical trial costs for RG2417 (bipolar depression), RG1068 (pancreatic imaging), and Friedreich's ataxia programs.
- Cash Position: Cash and cash equivalents decreased by $1.4 million during the quarter, though total liquid assets (including marketable securities) remain at approximately $62 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and investment balances are adequate to meet needs absent acquisitions. Future capital requirements depend on clinical study success and R&D progress.
- Outlook: The company expects R&D expenses to continue increasing as it advances three key therapeutic programs. Selling, general, and administrative expenses are expected to increase slightly in fiscal 2010 in preparation for the commercial launch of RG1068.
- Risks: Key risks include the uncertainty of pharmaceutical product development, dependence on third-party manufacturers, the success of clinical trials, and the ability to raise additional capital if needed. The company has a full valuation allowance against net operating losses due to uncertainty regarding future realization.
- Unusual Items: The Q2 2008 results were significantly impacted by the $5 million initial royalty payment from the Bristol settlement, making year-over-year comparisons of royalty revenue volatile.
Investor Verification Checklist
- Verify the sustainability of Protein A product revenue given the 55% decline attributed to economic conditions and customer demand.
- Confirm the timeline and funding requirements for the three active clinical programs (RG2417, RG1068, and Friedreich's ataxia) driving the 62% increase in R&D spend.
- Assess the remaining duration and potential revenue from the Bristol-Myers Squibb royalty agreement (expires Dec 2013) versus the one-time nature of the initial settlement payment.
- Review the company's cash burn rate relative to its $62 million in total liquid assets to determine runway without additional financing.
- Monitor the status of the stock repurchase program (757,173 shares remaining available) and any potential dilution from future equity issuances.